Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET
Company Participants
Bruce Greenberg - Interim Chief Financial Officer
Todd Brady - President and Chief Executive Officer
Conference Call Participants
Marc Goodman - SVB Securities
Yigal Nochomovitz - Citigroup
Justin Kim - Oppenheimer & Co.
Catherine Novack - Jones Research
Yale Jen - Laidlaw & Company
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After speakers' presentations, there will be a question-and-answer session.
I would now like to hand the call over to -- the conference call over to Mr. Bruce Greenberg, the company's Interim Chief Financial Officer. Please go ahead, Sir Bruce Greenberg.
Bruce Greenberg
Thank you, and good morning, everyone.
With me today is Dr. Todd Brady, our President and Chief Executive Officer.
This morning, we issued a press release reporting recent corporate highlights and our financial results for the year ended December 31, 2022. A copy of the press release is available on the Investors & Media section of our website at www.aldeyra.com.
Please note that this morning's conference call contains forward-looking statements regarding future events and the future performance of Aldeyra. Forward-looking statements include, but are not limited to, statements regarding FDA review of our drug applications -- of our new drug applications, potential commercialization, the anticipated timing of initiation of results from our clinical trials, our projected cash runway, our possible or assumed future results of operations, expenses and financial position, and potential growth opportunities.
These statements are based on the information available to us today and reflect our current views concerning future events. They are based on assumptions and subject to risks and uncertainties, including the development, clinical and regulatory plans or expectations for Aldeyra's product candidates and systems-based approaches. The risks that result from clinical trials or portions of clinical trials may not accurately predict the results of future trials for the same or different indications and Aldeyra is continuing review and quality control analysis of clinical data.
Aldeyra assumes no obligation to update these statements as circumstances change. Future events and actual results could differ materially from those projected in our forward-looking statements. Additional information concerning factors that could cause results to differ materially from our forward-looking statements are described in greater detail in our press release issued this morning and in our filings with the SEC.